SPRB (STOCKS)
Spruce Biosciences, Inc. Common Stock
$52.620000
+0.730000 (+1.41%)
Prev close: $51.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Javier Szwarcberg
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $136.40M
- Employees
- 20
- P/E (TTM)
- -1.32
- P/B (TTM)
- 2.06
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-8.94 | $-8.99 | +0.0523 | +0.58% |
|
Dec 2025 (Q4)
|
$-11.28 | $-8.15 | -3.1346 | -38.48% |
|
Sep 2025 (Q3)
|
$-14.58 | $-14.21 | -0.3663 | -2.58% |
|
Jun 2025 (Q2)
|
$-3.50 | $-19.51 | +16.0075 | +82.06% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $34.01M |
| Depreciation and Amortization | $267.00K |
| Research and Development | $16.26M |
| Other Operating Expenses | $17.49M |
| Operating Income/Loss | -$34.01M |
| Income/Loss From Continuing Operations After Tax | -$37.19M |
| Income/Loss From Continuing Operations Before Tax | -$37.19M |
| Interest Expense, Operating | $728.00K |
| Net Income/Loss | -$37.19M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$37.19M |
| Net Income/Loss Available To Common Stockholders, Basic | -$37.19M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$36.60 |
| Diluted Earnings Per Share | -$36.60 |
| Basic Average Shares | 2,703,365 |
| Diluted Average Shares | 2,703,365 |
| Assets | $56.17M |
| Current Assets | $55.03M |
| Cash | $54.10M |
| Prepaid Expenses | $864.00K |
| Other Current Assets | $68.00K |
| Noncurrent Assets | $1.13M |
| Liabilities | $21.52M |
| Current Liabilities | $11.78M |
| Accounts Payable | $2.68M |
| Other Current Liabilities | $9.10M |
| Noncurrent Liabilities | $9.73M |
| Long-term Debt | $20.41M |
| Equity | $34.65M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $34.65M |
| Liabilities And Equity | $56.17M |
| Net Cash Flow From Operating Activities | -$29.33M |
| Net Cash Flow From Operating Activities, Continuing | $29.30M |
| Net Cash Flow From Investing Activities | -$23.30M |
| Net Cash Flow From Investing Activities, Continuing | -$89.93M |
| Net Cash Flow From Financing Activities | $57.81M |
| Net Cash Flow From Financing Activities, Continuing | $57.81M |
| Net Cash Flow | $22.61M |
| Net Cash Flow, Continuing | $22.61M |
| Comprehensive Income/Loss | -$37.19M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$37.19M |
| Other Comprehensive Income/Loss | $0.00 |